RxDoctor Payments DataLook up a doctor →

Patricia Tu, DO

Family Medicine · Reno, NVNPI 1750875332

Payments from drug & device makers

$10,079in general payments, 2019–2025

Across 568 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Amgen$942
  • Pfizer$804
  • Boehringer Ingelheim$573
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$10,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,079 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$64,398
Medicare patients
210
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$133,694
EliquisApixaban63$80,779
JardianceEmpagliflozin49$67,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$63,979
FarxigaDapagliflozin Propanediol43$43,625
TrulicityDulaglutide32$43,073
JanuviaSitagliptin Phosphate20$25,894
XareltoRivaroxaban17$24,361
MounjaroTirzepatide15$24,031
LinzessLinaclotide15$13,873
Breo ElliptaFluticasone/Vilanterol26$12,702
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,961
MyrbetriqMirabegron18$11,801
Spiriva RespimatTiotropium Bromide12$9,216
SymbicortBudesonide/Formoterol Fumarate19$7,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,049$133,69493 claims
PfizerEliquis$804$80,77963 claims
Boehringer IngelheimJardiance, Spiriva Respimat$573$76,92061 claims
GSKTrelegy Ellipta, Breo Ellipta$145$76,681117 claims
Lilly USA, LLCTrulicity, Mounjaro$538$67,10547 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,197$62,73279 claims
MerckJanuvia$257$25,89420 claims
Johnson & JohnsonXarelto$148$24,36117 claims
AbbVieLinzess, Synthroid$2,039$15,55735 claims
Astellas Pharma US IncMyrbetriq$361$11,80118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →